DiaSorin (OTCMKTS:DSRLF) Downgraded by UBS Group to “Neutral”

Posted by Defense World Staff on Apr 10th, 2026

UBS Group cut shares of DiaSorin (OTCMKTS:DSRLF – Free Report) from a buy rating to a neutral rating in a research report report published on Thursday, MarketBeat Ratings reports.

A number of other equities research analysts have also recently commented on DSRLF. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of DiaSorin in a report on Tuesday, February 10th. BNP Paribas Exane upgraded DiaSorin to a “neutral” rating in a report on Wednesday, January 28th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Get Our Latest Analysis on DSRLF

DiaSorin Stock Performance

Shares of OTCMKTS:DSRLF opened at $67.00 on Thursday. The business’s fifty day moving average price is $77.48 and its two-hundred day moving average price is $80.05. DiaSorin has a one year low of $66.50 and a one year high of $112.30.

About DiaSorin

(Get Free Report)

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.